Gilead Sciences (FRA:GIS) Short Interest


FRA:GIS Gilead Sciences Inc FRA:GIS
75 GF Score
Price €109.12
GF Value €82.28
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:GIS vs AMGN, PFE, BMY: Short Interest Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Short Interest falls into.


FRA:GIS
75GF Score
Gilead Sciences Inc FRA:GIS
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gilead Sciences (FRA:GIS) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of €109.12 is trading 32.6% above its estimated GF Value™ of €82.28. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for FRA:GIS:

  • Short Interest:
  • GF Value™: €82.28 vs. price of €109.12 (32.6% above fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score

Get the complete analysis for FRA:GIS

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€109.12
Price
€82.28
GF Value